LONDON – September 3, 2016 – During the upcoming 2016 European Respiratory Society International Congress (ERS), ResMed will offer a world preview of its next generation AirFitTM mask series and highlight latest developments in its industry-leading connected care solutions.
ERS will mark the first public showing of the latest generation of ResMed’s award-winning range of masks for patients with sleep disordered breathing. Designed to fit faces of all shapes and sizes, the AirFitTM 20 series of masks provides a comfortable and robust seal even for the most challenging fittings. International studies found that AirFit N20 nasal mask and AirFit F20 full face mask fit 99.4% and 96.5% of all patients tested.2,3 The mask’s trademarked Infinity SealTM silicone cushion offers exceptional performance under the most difficult circumstances, including mis-fitting and patient movement during therapy.
ResMed celebrates two million connected patients and showcases connectivity for ventilators
ResMed connected care solutions provide a seamless therapy system – from screening and diagnosis to sleep and respiratory care treatment, and from patient management to patient engagement. In 2015 ResMed was named the world’s largest provider of connected healthcare solutions at home for remote patient monitoring1. It has connected more than two million patients with its positive airway pressure (PAP) therapy devices in the past two years through built-in wireless capability.
At ERS 2016, ResMed will showcase the connected care capabilities recently added to its home non-invasive ventilators.
“Connecting patients with their care provider has enormous potential to deliver better outcomes in major fields of health,” said Anne Reiser, president of ResMed’s EMEA-APAC region. “That’s why ResMed is investing in bringing that connectivity to our solutions across the board and working together with our customers and the medical community to harness the insights it brings.”
“In COPD for example, ResMed already offers a range of solutions for treating patients in the home via non-invasive ventilation,” Reiser said. “By adding connectivity to those devices, we’re providing systems that enable care providers to remotely monitor outcomes, communicate insights, and act on data effectively to optimize their patients’ therapy, provide them with better care and help keep them active.”
ResMed is holding the following practical symposium and workshops:
Monday, September 5
- Mini-symposium: Contemporary management of Home NIV in COPD and OHS, 17:30–19:00, Room J (North Hall)
- Workshop: “Innovation towards personalised sleep therapy”, 13:15–14:30, room P (South Hall)
- Workshop: “iVAPS in life support and telemedicine in ventilation”, 13:15–14:30, Room ICC Capital Suite 2+3 (Capital Suite Hall)
Tuesday, September 6
- Co-sponsored ResMed/Philips Mini-symposium: Home Non-Invasive Ventilation for COPD patients: New perspectives from the HOT-HMV Trial; 17:30–19:00, Room ICC Capital Suite 7 (Capital Suite Hall)
- Workshop: “The Orkney Islands to IntraOral Scanning – the latest topics in dental sleep medicine”; 13:15–14:30, ICC Capital Suite 1 (Capital Suite Hall)
- Workshop: “iVAPS in life support and telemedicine in ventilation”; 13:15–14:30, ICC Capital Suite 16 (Capital Suite Hall)
Oral communications and posters
ResMed is supporting the following communications:
SERVE-HF study: Adaptive servo-ventilation for central sleep apnea in systolic heart failure
Oral presentation: “Understanding SERVE-HF: a multistate analysis to explain mechanisms underlying increased mortality risk in patients randomised to adaptive servo-ventilation (ASV)”.
C. Eulenburg (Groningen, Netherlands)
Will be presented during an oral session: “Current challenges in thoracic surgery” on Monday, September 5, 10:45–12:45 in Room D, Session 359.
Poster: “Adaptive servo-ventilation (ASV) pressures and cardiovascular (CV) mortality risk in SERVE-HF”.
H. Woehrle (Blaubeuren, Germany)
Will be presented in the thematic poster session: “Technical aspects, compliance, and adherence to positive airway pressure in sleep apnoea” on Monday, September 5, 12:50–14:40 in Room T-13, Session 386, PA 2374.
Poster Discussion: “Adaptive servo-ventilation for central sleep apnea in systolic heart failure does not improve muscle sympathetic nerve activity. A SERVE-HF substudy”.
R. Tamisier (Grenoble, France)
Will be presented during a poster discussion session: “Effects of hypoxia and sleep apnoea on the lung, heart, and vessels” on Monday, September 5, 10:45–12:45 in Room ICC, Capital Suite 8, Session 366, PA 2083.
ORCADES Study: treatment of OSA with mandibular repositioning devices (MRD)
Poster: “Late-breaking abstract: Two-year follow-up (FU) results of ORCADES study: Long-term mandibular repositioning device (MRD) therapy in patients treated for obstructive sleep apnea (OSA)”.
V. Attali (Paris, France)
Will be presented in the thematic poster session: “Non-CPAP in obstructive and central sleep apnoea and obesity hypoventilation syndrome”; Monday, September 5, 12:50–14:40, T-14, Session 387, PA 2393.
ORCADES is a prospective, observational, multicentre cohort study of 369 OSA patients who refused or were noncompliant with CPAP and are instead being treated with the Narval™ CC MRD. Patients are followed for five years; reductions in AHI, improvement of sleep, symptoms and quality of life are being assessed, and side effects and adherence evaluated. Interim data show that Narval is efficacious and well tolerated.
FACE Study: a prospective, multicentre, observational cohort study in chronic HF patient population
Poster: “Late-breaking abstract: Morbidity and mortality of chronic heart failure (CHF) patients with central sleep apnoea (CSA) treated by adaptive servoventilation (ASV): interim results of FACE cohort study”.
R Tamisier (Grenoble, France)
Will be presented in the thematic poster session: “Technical aspects, compliance, and adherence to positive airway pressure in sleep apnoea” on Monday, September 5, 12:50–14:40, T-13, Session 386, PA 2373.
FACE is a French prospective, multicentre, observational cohort study that will provide long-term real-world data on morbidity and mortality in chronic HF (CHF) patients with reduced or preserved ejection fraction who are eligible for ASV therapy. So far roughly 400 patients have been enrolled, with a target of 600 CHF patients.
Polysomnographic assessment of automatic adjustable vs fixed EPAP intelligent volume assured positive airway pressure support in chronic hypoventilation
N. McArdle (Perth, Australia)
Will be presented in the thematic poster session: “Technical aspects, compliance, and adherence to positive airway pressure in sleep apnoea” on Monday, September 5, 12:50–14:40, T-13, Session 386, PA 2370.
ResMed’s booth is located at G.02.
Latest information about ResMed’s participation at ERS, including products to display, can be obtained via ResMed.com/ERS
1 Berg Insight, mHealth report 2015
2 ResMed AirFit N20 internal global fitting study of existing ResMed patients, conducted 12/11/2015 ; ID A3697629.
3 Preliminary patient study – data on file
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnoea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.